CH630807A5 - Verfahren zur herstellung eines antiserums. - Google Patents

Verfahren zur herstellung eines antiserums. Download PDF

Info

Publication number: CH630807A5
Authority: CH; Switzerland
Prior art keywords: neuraminidase; antigen; adjuvant; yes; germs
Prior art date: 1976-05-11

Application number

CH571377A

Other languages

German (de)

English (en)

Inventor

Juergen Dr Knob

Hans-Harald Dr Sedlacek

Friedrich Robert Dr Seiler

Original Assignee

Behringwerke Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-05-11

Filing date

1977-05-06

Publication date

1982-07-15

1977-05-06 Application filed by Behringwerke Ag filed Critical Behringwerke Ag

1982-07-15 Publication of CH630807A5 publication Critical patent/CH630807A5/de

Links

238000004519 manufacturing process Methods 0.000 title claims description 5
108010006232 Neuraminidase Proteins 0.000 claims description 45
102000005348 Neuraminidase Human genes 0.000 claims description 44
239000000427 antigen Substances 0.000 claims description 25
102000036639 antigens Human genes 0.000 claims description 25
108091007433 antigens Proteins 0.000 claims description 25
241001465754 Metazoa Species 0.000 claims description 11
238000000034 method Methods 0.000 claims description 5
210000002966 serum Anatomy 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 3
210000004369 blood Anatomy 0.000 claims description 3
239000008280 blood Substances 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
239000002671 adjuvant Substances 0.000 description 14
244000052616 bacterial pathogen Species 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
230000003053 immunization Effects 0.000 description 9
241000607626 Vibrio cholerae Species 0.000 description 8
230000028993 immune response Effects 0.000 description 8
238000002649 immunization Methods 0.000 description 8
229940118696 vibrio cholerae Drugs 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 6
230000000694 effects Effects 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
102000003886 Glycoproteins Human genes 0.000 description 5
108090000288 Glycoproteins Proteins 0.000 description 5
241000710799 Rubella virus Species 0.000 description 4
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 4
CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 3
230000000240 adjuvant effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000035931 haemagglutination Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000007123 defense Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
244000005700 microbiome Species 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
101001094887 Ambrosia artemisiifolia Pectate lyase 1 Proteins 0.000 description 1
101001123576 Ambrosia artemisiifolia Pectate lyase 2 Proteins 0.000 description 1
101001123572 Ambrosia artemisiifolia Pectate lyase 3 Proteins 0.000 description 1
101000573177 Ambrosia artemisiifolia Pectate lyase 5 Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
101000583741 Clostridium perfringens Sialidase Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000012404 Orosomucoid Human genes 0.000 description 1
108010061952 Orosomucoid Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102100028755 Sialidase-2 Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001514 detection method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940124452 immunizing agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CH571377A 1976-05-11 1977-05-06 Verfahren zur herstellung eines antiserums. CH630807A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2620649A DE2620649C3 (de)	1976-05-11	1976-05-11	Immunologisches Adjuvans

Publications (1)

Publication Number	Publication Date
CH630807A5 true CH630807A5 (de)	1982-07-15

Family

ID=5977559

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH571377A CH630807A5 (de)	1976-05-11	1977-05-06	Verfahren zur herstellung eines antiserums.

Country Status (17)

Country	Link
US (1)	US4510129A (2)
JP (1)	JPS52136914A (2)
AT (1)	AT363590B (2)
AU (1)	AU512240B2 (2)
BE (1)	BE854512A (2)
CA (1)	CA1077841A (2)
CH (1)	CH630807A5 (2)
DE (1)	DE2620649C3 (2)
DK (1)	DK204277A (2)
FR (1)	FR2350847A1 (2)
GB (1)	GB1569003A (2)
IE (1)	IE45145B1 (2)
IL (1)	IL52048A (2)
IT (1)	IT1075545B (2)
LU (1)	LU77295A1 (2)
NL (1)	NL7704998A (2)
NZ (1)	NZ184039A (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992003164A1 (en) *	1990-08-17	1992-03-05	The Wellcome Foundation Limited	Neuraminidase and galactose oxidase as vaccine adjuvant

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR68088B (2) *	1978-02-16	1981-10-30	Science Union & Cie
US4729893A (en) *	1984-12-26	1988-03-08	Robert L. Letcher	Enteric encapsulation of ancrod for oral administration
US20030108927A1 (en) *	2000-04-03	2003-06-12	Kathryn Leishman	Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US7078165B2 (en) *	2003-03-27	2006-07-18	Institut Pasteur	Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
GB0307989D0 (en) *	2003-04-07	2003-05-14	Mcewen Lab Ltd	Therapeutic composition
AU2013323472B2 (en) *	2012-09-28	2018-07-05	Ellis KLINE	Glycosidase regimen for treatment of infectious disease
CN109641038A (zh)	2016-07-01	2019-04-16	小利兰·斯坦福大学理事会	靶向细胞表面编辑的共轭物
EP3735458A4 (en)	2018-01-03	2022-04-27	Palleon Pharmaceuticals Inc.	RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF

1976
- 1976-05-11 DE DE2620649A patent/DE2620649C3/de not_active Expired
1977
- 1977-05-06 NL NL7704998A patent/NL7704998A/xx not_active Application Discontinuation
- 1977-05-06 CH CH571377A patent/CH630807A5/de not_active IP Right Cessation
- 1977-05-09 IL IL52048A patent/IL52048A/xx unknown
- 1977-05-09 LU LU77295A patent/LU77295A1/xx unknown
- 1977-05-09 GB GB19294/77A patent/GB1569003A/en not_active Expired
- 1977-05-09 NZ NZ184039A patent/NZ184039A/xx unknown
- 1977-05-09 IT IT23350/77A patent/IT1075545B/it active
- 1977-05-10 AT AT0332577A patent/AT363590B/de not_active IP Right Cessation
- 1977-05-10 IE IE951/77A patent/IE45145B1/en not_active IP Right Cessation
- 1977-05-10 FR FR7714243A patent/FR2350847A1/fr active Granted
- 1977-05-10 AU AU25033/77A patent/AU512240B2/en not_active Expired
- 1977-05-10 CA CA278,034A patent/CA1077841A/en not_active Expired
- 1977-05-10 DK DK204277A patent/DK204277A/da not_active Application Discontinuation
- 1977-05-11 JP JP5416377A patent/JPS52136914A/ja active Granted
- 1977-05-11 BE BE177483A patent/BE854512A/xx not_active IP Right Cessation
1982
- 1982-08-09 US US06/406,531 patent/US4510129A/en not_active Expired - Lifetime

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992003164A1 (en) *	1990-08-17	1992-03-05	The Wellcome Foundation Limited	Neuraminidase and galactose oxidase as vaccine adjuvant
US6383498B1 (en)	1990-08-17	2002-05-07	Glaxo Wellcome Inc.	Compositions for vaccines

Also Published As

Publication number	Publication date
AU512240B2 (en)	1980-10-02
IE45145L (en)	1977-11-11
NL7704998A (nl)	1977-11-15
JPS52136914A (en)	1977-11-16
IE45145B1 (en)	1982-06-30
JPS624371B2 (2)	1987-01-30
AU2503377A (en)	1978-11-16
IT1075545B (it)	1985-04-22
LU77295A1 (2)	1977-12-13
ATA332577A (de)	1981-01-15
IL52048A (en)	1980-11-30
DE2620649A1 (de)	1977-11-17
FR2350847B1 (2)	1980-02-29
IL52048A0 (en)	1977-07-31
US4510129A (en)	1985-04-09
FR2350847A1 (fr)	1977-12-09
CA1077841A (en)	1980-05-20
DE2620649C3 (de)	1980-11-06
BE854512A (fr)	1977-11-14
DE2620649B2 (de)	1980-03-13
GB1569003A (en)	1980-06-11
DK204277A (da)	1977-11-12
NZ184039A (en)	1980-04-28
AT363590B (de)	1981-08-10

Legal Events

Date	Code	Title	Description
1994-01-31	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE69128782T2 (de)	1998-09-10	Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff
AT408615B (de)	2002-01-25	Neue influenzavirus-impfstoffzusammensetzung
DE69620001T2 (de)	2002-11-21	Impfstoffe gegen grippe
AT407958B (de)	2001-07-25	Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
DE68911019T2 (de)	1994-05-19	Kombiniertes Hepatitis A- und B-Vakzin mit Adjuvans.
EP0331102B1 (de)	1993-06-23	Virusmodifizierte Tumorvakzinen für die Immuntherapie von Tumormetastasen
DE3200813A1 (de)	1982-08-12	"synthetischer impfstoff gegen virusinfektionen"
DE3911442A1 (de)	1989-11-02	Impfstoff-praeparation
EP0304786A2 (de)	1989-03-01	Intranasale Impfung von Pferden mit inaktivierten Mikroorganismen oder antigenem Material
DE69528074T2 (de)	2003-04-30	Chitosan induzierte verstärkung
DE69232969T2 (de)	2004-08-05	Methode zur herstellung von gram-negativen bakteriellen vakzinen
DE2620649C3 (de)	1980-11-06	Immunologisches Adjuvans
DE3882781T2 (de)	1993-11-11	Impfstoff gegen Pasteurella.
DE3587681T2 (de)	1994-07-07	Vakzine und Serum für Endotoxin assoziierte Krankheit und Verfahren zur Herstellung derselben sowie Verfahren zur Immunisierung und Behandlung solcher Krankheiten, enttoxifierte Endotoxine und bakterielle Mutante.
DE2547105A1 (de)	1976-05-06	N-acetyl-muramyl-l-alanyl-d-isoglutamin enthaltende oelfreie adjuvanzien
DE3786301T2 (de)	1993-09-30	Kombinierter Impfstoff.
DE1617545C2 (de)	1983-11-03	Verwendung von informatorischer Ribonucleinsäure als Vaccine
DE3122669A1 (de)	1982-02-11	"verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2"
DE1792256C3 (de)	1979-07-05	Oral applizierbare, polyvalente Impfstoffe gegen lokale Darminfektionen
DE1492243C3 (de)	1979-08-16	Injizierbare Impfstoffe
DE69116155T2 (de)	1996-09-05	Neuramidase und glulaktoseoxidase als vaccinadjuvans
DE1902590C2 (de)	1984-04-26	Verwendung einer Immunribonucleinsäure (IRNS) zum Immunisieren lebender Tiere
CH660125A5 (de)	1987-03-31	Gereinigtes, entgiftetes endotoxin enthaltende zusammensetzung.
DE2034118A1 (en)	1972-01-13	Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
EP0271447B1 (de)	1993-03-10	Vorbeugende Massnahmen zur Verhinderung der "Komplexen Respiratorischen Erkrankung bei Rindern" durch Verabreichung von Interferon